Browse Drug Recalls
14,380 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 14,380 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 14,380 FDA drug recalls, Class II.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Jan 18, 2019 | Irbesartan and Hydrochlorothiazide Tablets, USP 300/12.5 mg Rx Only Manufactu... | CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained ... | Class II | Prinston Pharmaceutical Inc |
| Jan 18, 2019 | Fexofenadine HCl Tablets, USP, 180 mg, packaged in a) 30-count bottles (NDC 0... | Failed Impurities/Degradation Specifications: Related compound results obtained during routine st... | Class II | Mylan Pharmaceuticals Inc. |
| Jan 18, 2019 | Irbesartan Tablets 300 mg 90 count Rx only Manufactured by: Zhejiang Huah... | CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained ... | Class II | Prinston Pharmaceutical Inc |
| Jan 18, 2019 | Irbesartan and Hydrochlorothiazide Tablets, USP 300/12.5 mg Rx Only Manufactu... | CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained ... | Class II | Prinston Pharmaceutical Inc |
| Jan 18, 2019 | Irbesartan and Hydrochlorothiazide Tablets, USP 150/12.5 mg Rx 30 Tablets Onl... | CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained ... | Class II | Prinston Pharmaceutical Inc |
| Jan 18, 2019 | Alprazolam Tablets, USP, 0.25 mg, 10x10 per carton, Rx Only, Manufactured for... | Failed Impurities/Degradation Specifications: Elevated levels of a known impurity detected durin... | Class II | Mylan Institutional, Inc. (d.b.a. UDL Laborator... |
| Jan 18, 2019 | Irbesartan and HydrochlorothiazideTablets, USP 150/12.5 mg Rx Only 90 count ... | CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained ... | Class II | Prinston Pharmaceutical Inc |
| Jan 16, 2019 | Docusate Sodium, 100mg softgels, packaged in 10 x 10 unit dose blister cards,... | Labeling: Label mix-up: Secondary carton may be labeled as Gabapentin 300mg instead of Docusate S... | Class II | Rx Pak Division of McKesson Corporation |
| Jan 16, 2019 | NORepinephrine 16 mg added to 0.9% Sodium Chloride (PF), 16 mg / 250 mL, 250 ... | Labeling: Label mix-up | Class II | KRS Global Biotechnology, Inc |
| Jan 16, 2019 | NORepinephrine 4 mg added to 5% Dextrose 250 mL Bag (PF), 4 mg / 250 mL, 250 ... | Labeling: Label mix-up | Class II | KRS Global Biotechnology, Inc |
| Jan 15, 2019 | infants* IBUPROFEN, Concentrated Ibuprofen Oral Suspension, USP (NSAID), 50 m... | Superpotent Drug: recalled lots may have higher concentration of ibuprofen than amount labeled. | Class II | Tris Pharma Inc. |
| Jan 15, 2019 | Infants' Ibuprofen, Concentrated Ibuprofen Oral Suspension, USP, (NSAID), 50 ... | Superpotent Drug: recalled lots may have higher concentration of ibuprofen than amount labeled. | Class II | Tris Pharma Inc. |
| Jan 15, 2019 | Infants' Ibuprofen, Concentrated Ibuprofen Oral Suspension, USP, (NSAID), 50 ... | Superpotent Drug: recalled lots may have higher concentration of ibuprofen than amount labeled. | Class II | Tris Pharma Inc. |
| Jan 15, 2019 | Fluocinolone Acetonide Topical Solution, USP, 0.01 %, 60 mL bottle, Rx Only, ... | Failed Impurities/Degradation Specifications: Expansion of October 2018 recall due to elevated ou... | Class II | LUPIN SOMERSET |
| Jan 15, 2019 | HEPERAIN 50 mg/50 mL (1mg/mL) Injectable Solution, Heparin Sodium 0.45% Sodiu... | Labeling; Label Error on Declared Strength; label incorrectly states the concentration as 50 mg/5... | Class II | Advanced Pharma Inc. |
| Jan 15, 2019 | Ezetimibe and Simvastatin Tablets 10mg/80 mg, 1000-count bottles, Rx only, M... | Presence of Foreign Substance: Product complaint of black speckles observed on tablets. | Class II | Dr. Reddy's Laboratories, Inc. |
| Jan 10, 2019 | Losartan Potassium Tablets, USP. 50 mg. NDC# 0904-6390-61. Rx only. 100 count... | CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in... | Class II | MAJOR PHARMACEUTICALS |
| Jan 10, 2019 | Lipoic Acid Injection (aka Alpha Lipoic Acid or Thioctic Acid), 1,200 mg/30 m... | Presence of Particulate Matter: filmy/cloudy particulate observed in vial. | Class II | McGuff Compounding Pharmacy Services, Inc. |
| Jan 9, 2019 | Cephalexin for Oral Suspension USP 250mg/5 mL, Rx Only Manufactured for: Lu... | CGMP Deviations; presence of extraneous material in the was observed in area that is between the... | Class II | Lupin Pharmaceuticals Inc. |
| Jan 7, 2019 | Cephalexin for Oral Suspension USP, 250mg/5mL, 200 mL (when mixed), Rx only, ... | CGMP Deviation; manufacturing batch record could not be located | Class II | Lupin Pharmaceuticals Inc. |
| Jan 2, 2019 | 0.9% Buffered Lidocaine HCl (buffered in 8.4% Sodium Bicarbonate) a.) 1 mL in... | Subpotent | Class II | PharMEDium Services, LLC. |
| Jan 2, 2019 | Dianeal Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextro... | Lack of Assurance of Sterility: Confirmed customer complaints for leaks on the tubing. | Class II | Baxter Healthcare Corporation |
| Jan 2, 2019 | Lidocaine/Epinepherine liquid 1%/ 1:1000, RX, glass vial These include inj... | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Epinephrine liquid 1:1000, RX, glass vial | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Cyclosporin liquid 1%, Rx, plastic dropper bottle | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Cyclosporin liquid 0.5%, Rx, plastic dropper bottle | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Cefdinir for Oral Suspension USP, 125mg/5mL, packaged in a) 60mL (NDC 68180-7... | CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to ... | Class II | Lupin Pharmaceuticals Inc. |
| Jan 2, 2019 | Cidofovir Injection 375mg/5mL (75mg/mL) vial injection. 5 mL vials, Rx only, ... | Lack of Assurance of Sterility: complaints received about dried powder on the outside of bottle | Class II | Heritage Pharmaceuticals, Inc. |
| Jan 2, 2019 | Methocarbamol liquid 100mg/ml, RX, glass vial | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Cefdinir for Oral Suspension USP, 250mg/5mL, packaged in a) 60mL (NDC 68180-7... | CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to ... | Class II | Lupin Pharmaceuticals Inc. |
| Jan 2, 2019 | Lidocaine gel 2%, RX, plastic dropper | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Hydroxyprogesterone liquid, 250mg/ml, RX, glass vial | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Glutathione liquid, 200mg/ml, Rx | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | MIC B vitamin liquid 25/50/50/1/1/1mg/ml RX glass vial | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Lidocaine gel 1%, RX, plastic dropper | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | HCG liquid, 1000u/ml, RX, glass vial, various | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Testosteron Cypionate liquid 200mg/ml, RX, glass vial | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Cyclosporin liquid 2%, Rx, plastic dropper bottle, dry eye | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Cyclosporin liquid 0.2%, Rx, plastic dropper bottle | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Cyclosporin liquid 0.05%, Rx, plastic dropper bottle | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Vitamin B12 liquid 1000mcg/ml, RX, glass vial | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Jan 2, 2019 | Glutathione liquid, 100mg/ml | Lack of sterility assurance. | Class II | Hiers Enterprises, LLC dba Northwest Compoundin... |
| Dec 31, 2018 | Valsartan tablets USP 320 mg, 90-count bottles, Rx Only, Manufactured for: Au... | CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained ... | Class II | Aurobindo Pharma USA Inc. |
| Dec 31, 2018 | Amlodipine and Valsartan Tablets USP 10 mg/320 mg. 30-count bottles, Rx Only,... | CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained ... | Class II | Aurobindo Pharma USA Inc. |
| Dec 31, 2018 | Valsartan Tablets USP 40 mg, 30 count bottles, Rx only, Distributed by: Auro... | GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethy... | Class II | Aurobindo Pharma USA Inc. |
| Dec 31, 2018 | Amlodipine and Valsartan Tablets USP 10mg/160mg, 30 count bottles, Manufactur... | GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethy... | Class II | Aurobindo Pharma USA Inc. |
| Dec 31, 2018 | Valsartan Tablets USP 160 mg, 90 count bottles, Rx only, Distributed by: Auro... | GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethy... | Class II | Aurobindo Pharma USA Inc. |
| Dec 31, 2018 | Valsartan and Hydrochlorothiazide tablets USP 160 mg/25 mg, 90-count bottle, ... | CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained ... | Class II | Aurobindo Pharma USA Inc. |
| Dec 31, 2018 | Valsartan and Hydrochlorothiazide tablets USP 160mg/12.5 mg, 90-count bottle,... | CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained ... | Class II | Aurobindo Pharma USA Inc. |
| Dec 31, 2018 | Amlodipine and Valsartan Tablets USP 5 mg/320 mg, 30-count bottles, Rx Only, ... | CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained ... | Class II | Aurobindo Pharma USA Inc. |
Frequently Asked Questions
When a drug safety issue is identified, through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks, the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.